DEF: CytoSorbents 2026 Proxy: Reverse Split and Board Election

CytoSorbents Corporation has scheduled its 2026 Annual Meeting for August 13, 2026, to vote on director elections, executive compensation, and a proposed reverse stock split.

Summary

• The 2026 Annual Meeting of Stockholders is scheduled for August 13, 2026, to be held virtually.
• Stockholders will vote on the election of five directors: Phillip P. Chan, Michael G. Bator, Edward R. Jones, Alan D. Sobel, and Jiny Kim.
• The company is seeking approval for a reverse stock split at a ratio between 1-for-5 and 1-for-20 to maintain Nasdaq listing compliance.
• The company reported a net loss of $8,197,439 for the fiscal year ended December 31, 2025.
• The company has 62,842,748 shares of common stock issued and outstanding as of the June 15, 2026 record date.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a defensive filing, as the primary focus is on maintaining listing compliance through a reverse stock split and managing liquidity constraints.

Positives

• The company has successfully maintained its Nasdaq listing through an extension granted until September 28, 2026.
• The company has successfully completed rights offerings in January and April 2025 to bolster liquidity.
• The board has implemented cost-cutting measures, including a voluntary salary reduction program for executives in 2024.

Negatives

• The company reported a net loss of $8,197,439 for 2025, following losses of $20,718,957 in 2024 and $29,246,760 in 2023.
• The common stock price has fallen below the $1.00 minimum bid price requirement for Nasdaq listing.
• The company has deferred payment of executive bonuses for 2024 and 2025 due to liquidity constraints.

Risks

• Potential delisting from Nasdaq if the minimum bid price requirement is not met by September 28, 2026.
• The reverse stock split may not result in a sustained increase in share price and could negatively impact liquidity.
• The company expects it may need to raise additional capital in the future to fund ongoing operations.
• The company has limited direct competitors but competes for capital with other early-stage life sciences companies.

Future Outlook

The company intends to pursue regulatory approval of DrugSorb-ATR with the FDA and Health Canada, and expects it may need to raise additional capital to fund ongoing operations.

Management Comments

• The Board believes the reverse stock split is an effective tool to maintain Nasdaq listing and facilitate future capital raising.
• The Board believes the virtual meeting format facilitates broader stockholder participation.

Industry Context

StockSavvy.ai notes that CytoSorbents is navigating the common challenges of microcap life sciences companies, specifically the struggle to maintain Nasdaq listing compliance while managing cash burn and seeking regulatory approval for pipeline products.

Comparison to Industry Standards

• The company's reliance on reverse stock splits to maintain listing compliance is a common, albeit often dilutive, strategy among distressed small-cap biotech firms.
• The company's compensation structure, including the use of stock options and restricted stock units, is consistent with industry standards for early-stage life sciences companies.

Corporate Governance

Stakeholder Impact

• Shareholders face potential dilution and the impact of a reverse stock split on share price and liquidity.
• Employees and executives are subject to deferred bonus payments due to liquidity constraints.

Next Steps

• Hold the Annual Meeting of Stockholders on August 13, 2026.
• Implement the reverse stock split if approved by stockholders and deemed necessary by the Board.
• Continue efforts to regain Nasdaq listing compliance by September 28, 2026.

Key Dates

Recommendation

The company is in a precarious financial position, evidenced by recurring losses and the need for a reverse stock split to maintain listing. Investors should hold until there is clear evidence of regulatory progress for DrugSorb-ATR or improved financial stability.

Keywords

CytoSorbents, CTSO, Reverse Stock Split, Proxy Statement, Nasdaq Listing, Biotechnology, Blood Purification